| 000 | 01464 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517151219.0 | ||
| 264 | 0 | _c20170605 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1746-045X | ||
| 024 | 7 |
_a10.1080/17460441.2017.1322061 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTalens, Francien | |
| 245 | 0 | 0 |
_aTherapeutic targeting and patient selection for cancers with homologous recombination defects. _h[electronic resource] |
| 260 |
_bExpert opinion on drug discovery _cJun 2017 |
||
| 300 |
_a565-581 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBRCA1 Protein _xgenetics |
| 650 | 0 | 4 |
_aBRCA2 Protein _xgenetics |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDNA Breaks, Double-Stranded |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aRecombinational DNA Repair _xgenetics |
| 700 | 1 | _aJalving, Mathilde | |
| 700 | 1 | _aGietema, Jourik A | |
| 700 | 1 | _aVan Vugt, Marcel A | |
| 773 | 0 |
_tExpert opinion on drug discovery _gvol. 12 _gno. 6 _gp. 565-581 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/17460441.2017.1322061 _zAvailable from publisher's website |
| 999 |
_c27096274 _d27096274 |
||